CClinicalTrials.gg
Status unknownNCT03866122Updated Sep 10, 2021

Evaluation of a Novel Neonatal Temperature Monitor

An interventional study of NTM Monitoring in Neonatal Hypothermia, sponsored by William Marsh Rice University. Status unknown at 1 site in United States. Open to participants aged Up to 28 Days. Per ClinicalTrials.gov, last updated 2021-09-10.

Sponsored by William Marsh Rice University · Not applicable, Interventional, and Device feasibility

The sponsor has not verified this record recently (last verified Sep 2021), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 1 year 3 months after the study started (first participant enrolled Sep 2017, registered Jan 2019).
Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Not applicable
Ages
Up to 28 Days
Sex
All
01

Study summary

A team of researchers at Rice University and Queen Elizabeth Central Hospital (QECH) are working to develop a low-cost temperature sensor that can continuously monitor an infant's temperature (NTM). This robust, low-cost device will allow for the individualized monitoring of each infant with alerts for hypo and hyperthermia. A reusable band placed around the infant's abdomen to hold the temperature sensor will eliminate disposable components. This study will assess the accuracy of this novel device against a gold standard (Philips Intellivue patient monitor) and up to two existing devices (Bempu and Thermospot).

Read the detailed description

This study will assess the accuracy of this novel device against a commercially available patient monitor (Philips Intellivue MP30). Results will be compared to that of two existing devices designed for low resource settings: Bempu, a temperature monitor placed around an infant's wrist; and Thermospot, a sticker that changes color with temperature.

This study will enroll up to 150 infants at Queen Elizabeth Central Hospital. Up to 75 subjects will be collected from the neonatal ward and 75 subjects from the Kangaroo Mother Care (KMC) ward. This sample size will ensure that the investigators are able to collect sufficient data from infants with a range of gestational ages, weights, temperatures, and treatment locations (ie open cot, radiant warmer). The data from this study can be used to calculate the sample size needed in a larger study to evaluate changes in outcomes and nurse behavior related to the different temperature monitors (NTM, Bempu, Thermospot).

During the trial, the following steps will be taken:

A trained study nurse will assess the subject for clinical complications before attaching the temperature monitoring devices.

  1. A trained study nurse or clinician will attach the test temperature monitoring devices to the infant. A trained research assistant from Rice University or from the Biomedical Engineering Department at Malawi Polytechnic will observe all procedures and will notify the nurse of any observed errors so they may be corrected. They will also be able to answer any technical questions from the nurse. If there is any concern for the comfort or skin of the infant, only one device may be placed on at a time (NTM, Bempu, ThermoSpot).
  2. The trained study nurse will attach the temperature probe from the commercial gold standard as well as provide any other care needed.
  3. A research assistant will use a laptop to collect data from the continuous temperature monitors (NTM and gold standard). The nurse will record the temperature readings every hour from all monitors on paper forms along with the standard of care.
  4. Each time an alarm sounds from any device (Bempu and the commercial gold standard have audible alarms), the nurse will record all temperature values including a reading taken with the standard of care method. If the subject is found to be hyper/hypothermic, the nurse will respond with the appropriate standard of care.
  5. Temperature monitoring will continue for up to 3 days. The research assistant may ask the nurse to remove and reapply the temperature probes during this period.

The goal of this study is to confirm the accuracy of these temperature monitors. Target accuracy for NTM device is +/- 0.5 C. In order to confirm this temperature accuracy in the settings of both the neonatal ward and the KMC ward, 75 subjects are needed in each setting. The international standards for clinical thermometers, standard number 80601-2-56, requires that 75 subjects from each patient population be tested to demonstrate the clinical accuracy of the thermometer. The clinical accuracy is reported using a measure of bias as well as the limits of agreement.

02

Conditions studied

  • Neonatal Hypothermia

Browse trials for

03

In context

Hypothermia

499 studies on the registry are indexed under Hypothermia; 54 are open to participants now.

This study's planned enrollment of 150 is above the median of 80 across 351 interventional studies indexed under Hypothermia.

Browse Hypothermia studies →

Lead sponsor

William Marsh Rice University is the lead sponsor of 17 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 28 Days
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • The subject is currently being treated at QECH in the neonatal or KMC ward.
  • Study devices are available for use.
  • The subject's caregiver has provided informed consent for their child to participate.

Exclusion criteria

Exclusion Criteria:

  • At the clinician's discretion for any reason including, but not limited to:
  • potential for skin irritation
  • Cough
  • other condition that may preclude use of the temperature belt
  • concurrent treatments that may require increased patient care
05

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Neonatal Temperature Monitor

    One or more test devices (NTM, Bempu, Thermospot) will be attached to the infant in the neonatal intensive care unit (NICU) or KMC ward along with the Philips Intellivue patient monitor. Temperature will be monitored continuously using each device for up to 72 hours.

    Device: NTM Monitoring

Interventions

  • DeviceNTM Monitoring

    NTM and a patient monitor will continuously collect temperature for up to 72 hours. Additionally, Bempu and Thermospot may monitor temperature for up to 72 hours.

06

What researchers measure

Primary outcomes

  1. Temperature measurement accuracy

    Continuously measured temperature for test devices compared against Philips Intellivue patient monitor

    Time frame: <72 hours

07

Study locations

1 of 1 sites recruiting
  • Rice University
    Houston, Texas 77030, United States
    Recruiting
08

References and documents

Publications

  • Sosa Saenz SE, Hardy MK, Heenan M, Oden ZM, Richards-Kortum R, Dube Q, Kawaza K. Evaluation of a continuous neonatal temperature monitor for low-resource settings: a device feasibility pilot study. BMJ Paediatr Open. 2020 May 7;4(1):e000655. doi: 10.1136/bmjpo-2020-000655. eCollection 2020. PubMed 32426530 ↗

Study documents

  • Protocol and statistical analysis plan · Apr 1, 2017
  • Informed consent form · Apr 21, 2017

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 10, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03866122
Lead sponsor
William Marsh Rice University
Collaborators
Kamuzu University of Health Sciences
Responsible party
Sponsor
First posted
Mar 7, 2019
Start date
Sep 6, 2017
Primary completion
Sep 6, 2022 (estimated)
Completion
Sep 6, 2022 (estimated)
Last update
Sep 10, 2021

Study contacts

Rebecca Elias, MPH
Contact
rebecca.elias@rice.edu
713-348-6574
Rebecca Richards-Kortum, PhD
principal investigator · William Marsh Rice University
Queen Dube, MD
principal investigator · Kamuzu University of Health Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion